Sonoma Biotherapeutics

Executive Summary

Sonoma Biotherapeutics is a clinical-stage biotechnology company pioneering engineered regulatory T cell (Treg) therapies to restore immune balance in autoimmune and inflammatory diseases. Founded in 2019 by leading Treg biologists, the company leverages a proprietary platform to generate targeted, durable cell therapies. Its most advanced program, SBT-101, is an autologous Treg therapy engineered to target rheumatoid arthritis (RA) and is currently being evaluated in a Phase 1 clinical trial. The trial aims to assess safety and early efficacy, with initial data expected in the coming year. Sonoma's pipeline also includes preclinical programs in type 1 diabetes and inflammatory bowel disease, addressing significant unmet medical needs where conventional treatments often fail to achieve durable remission. The company's approach leverages the natural immunosuppressive functions of Tregs, engineered for enhanced specificity and stability. Sonoma's platform includes proprietary tools for TCR selection, genetic engineering, and cell manufacturing, positioning it as a leader in the emerging Treg therapy space. With a strong scientific foundation and a first-in-class asset in the clinic, Sonoma has attracted investment from top-tier life science investors. Success in its Phase 1 RA trial would validate the Treg modality and de-risk its broader pipeline, potentially leading to partnerships or further financing. The company's ability to demonstrate safety, tolerability, and early signs of efficacy in RA will be a critical inflection point.

Upcoming Catalysts (preview)

• Q3 2026Phase 1 safety and efficacy data readout for SBT-101 in rheumatoid arthritis60% success
• Q4 2026IND filing for Type 1 diabetes Treg therapy program70% success
• TBDPotential strategic partnership or collaboration for Treg platform50% success